1) Development of retroviral vectors for gene therapy and vaccine applications. Specifically, lab works with recombinant foamy virus vectors expressing HIV-1 gag proteins. Studies involve both in vitro characterization and optimization of these vectors as well as small animal model studies.
2) Clinical trials (phase II and III) of investigational antiretroviral agents for treatment of HIV infection.
3) Clinical trials of therapeutic vaccines for HIV infection.
Laboratory research focused on developing recombinant foamy virus vectors has demonstrated the gene therapy and vaccine vector potential of this nonpathogenic retrovirus as a useful replication-competent, integrating vector. These studies also set the stages for further pre-clinical studies in small animal models.
Clinical research has identified, characterized and help approve safe and effective novel anti-HIV treatments.
Lab develops recombinant foamy virus vectors expressing HIV-1 gag proteins.
Clinical research focuses on phase II and III clinical trials of investigational antiretroviral agents amd therapeutic vaccines.
© Copyright 2000-2007 Cedars-Sinai Health System. All rights reserved.
Terms and Conditions